Ray Dalio
BCRX icon

Ray Dalio’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ray Dalio’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.91M Sell
491,057
-146,997
-23% -$1.33M 0.02% 487
2026
Q1 		$6.07M Buy
638,054
+402,482
+171% +$3.13M 0.03% 370
2025
Q4 		$1.84M Sell
235,572
-175,931
-43% -$1.27M 0.01% 784
2025
Q3 		$3.12M Buy
+411,503
New +$3.43M 0.01% 608

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Ray Dalio's BCRX Position: Q2 2026 in Review

Ray Dalio reduced its BioCryst Pharmaceuticals (BCRX) stake by 23% in Q2 2026, selling an estimated $1.33M and leaving 491,057 shares worth $4.91M. The position accounts for 0.02% of the portfolio, ranked #487.

Ray Dalio first reported a position in BCRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $6.07M in Q1 2026. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Ray Dalio held 491,057 shares of BioCryst Pharmaceuticals worth $4.91M as of Q2 2026.
  • Ray Dalio sold 146,997 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.33M.
  • BioCryst Pharmaceuticals made up 0.02% of Ray Dalio's portfolio in Q2 2026, its #487 holding.
  • Ray Dalio first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Ray Dalio's BioCryst Pharmaceuticals position peaked at $6.07M in Q1 2026.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.